Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573803 | 0.87 | MAPT (0.61) | MAPTHPGDCYP3A4NOS1LMNA | |
| SCHEMBL30833662 | 0.81 | DAO (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL921416 | 0.81 | DAO (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL29431208 | 0.81 | JAK2 (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL2931498 | 0.81 | JAK2 (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL8597936 | 0.81 | MAP2K7 (0.48) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL588431 | 0.80 | PARP1 (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL2595091 | 0.80 | MAPT (0.50) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL29395331 | 0.80 | MAPT (0.50) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL1176140 | 0.80 | MAPT (0.50) | MAPTHPGDDAOCYP3A4NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7968719-B2 | Indazole derivatives as inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| EP-1713779-B1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090215824-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7528155-B2 | Indazole derivatives as inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| US-5583152-A | Use of N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl)-3 -methoxybenzoyl)-2-methyl-benzenesulphonamide, zafirlukast; allergic asthma, inflammatory diseases, endotoxic conditions or traumatic shock | ZENECA INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5440035-A | Leukotriene antagonists; antiallergens, antiinflammatory agents | ZENECA INC. (GB) | 1995-08-08 | — | — | US | disclosed |
| US-5391758-A | Leukotriene antagonists | ZENECA, INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5338734-A | Leukotriene antagonist properties; antiinflammatory agents | ZENECA INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5179112-A | Leukotriene antagonist as antiallergens and antiinflammatory agents | ICI AMERICAS INC. (US) | 1993-01-12 | — | — | US | disclosed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | disclosed |
| US-5030643-A | Antiallergens, antiinflammatory agents | ICI AMERICAS INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | MAPT 4726/4885HPGD 125/4885DAO 427/4885 |
| US-20090215824-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE | LIPE, PNLIP, CEL | MAPT 4206/4885HPGD 291/4885DAO 1183/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | MAPT 4726/4885HPGD 125/4885DAO 427/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | MAPT 3731/4885HPGD 250/4885DAO 319/4885 |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | MAPT 4206/4885HPGD 291/4885DAO 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.